Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 4 of 18
Next
>>
>
76 to 100 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC70	Everolimus	1	72	flat	flat	HCC70 everolimus 0 1 72	8	1.366	Inf	0.569	0.354	0.0	0.569	0.01	0.623	0.0534	0.643	Inf	0.718	0.766	0.0	0.718	0.01	0.62	0.0547	0.765
BT-20	KIN001-244	3	72	flat	flat	BT20 KIN001-244 0 3 72	8	2.608	Inf	0.841	0.062	0.0	0.841	0.01	0.489	0.133	0.935	Inf	0.805	0.922	0.0	0.805	0.01	0.475	0.145	0.919
BT-20	Sirolimus	2	72	flat	flat	BT20 rapamycin 0 2 72	8	1.952	Inf	0.421	0.579	0.0	0.421	0.01	NA	NA	0.421	Inf	0.513	0.513	0.0	0.513	0.01	NA	NA	0.513
HCC70	Everolimus	3	72	sigmoid	sigmoid	HCC70 everolimus 0 3 72	8	2.401	530906.0	0.749	0.195	0.072	0.603	0.1	0.706	0.0255	NA	381983.0	0.725	0.782	0.0137	0.59	0.1	0.706	0.0255	NA
Hs 578T	Everolimus	2		sigmoid	sigmoid	Hs578T everolimus 2	8	2.550	3210000000.0	0.626	0.335	0.000205	0.476	0.1	0.791	0.00913	NA	18938.0	0.59	0.627	0.000153	0.422	0.1	0.745	0.0166	NA
Hs 578T	Everolimus	1		sigmoid	sigmoid	Hs578T everolimus 1	8	2.030	1707115.0	0.626	0.318	0.00576	0.429	0.1	0.895	0.00116	NA	2.51e+21	0.657	0.704	0.00121	0.502	0.1	0.893	0.00124	NA
BT-549	Everolimus	1	72	sigmoid	sigmoid	BT549 everolimus 0 1 72	8	1.772	5.64	0.503	0.444	1e-05	0.367	0.1	0.911	0.000706	NA	437200.0	0.603	0.641	0.000146	0.444	0.1	0.858	0.00286	NA
HCC38	Everolimus	3	72	sigmoid	sigmoid	HCC38 everolimus 0 3 72	8	1.437	5.11	0.511	0.429	0.000567	0.299	0.1	0.934	0.000284	NA	573000000.0	0.668	0.707	0.000349	0.53	0.1	0.932	0.000308	NA
HCC70	Sirolimus	3	72	sigmoid	sigmoid	HCC70 rapamycin 0 3 72	8	2.548	310.0	0.732	0.227	0.000433	0.63	0.1	0.676	0.034	NA	22876.0	0.693	0.736	0.000237	0.58	0.1	0.659	0.0397	NA
HCC38	Sirolimus	3	72	sigmoid	sigmoid	HCC38 rapamycin 0 3 72	8	1.420	86.3	0.535	0.403	0.000236	0.361	0.1	0.901	0.000982	NA	75575.0	0.687	0.727	0.000198	0.569	0.1	0.889	0.00136	NA
BT-549	Sirolimus	1	72	sigmoid	sigmoid	BT549 rapamycin 0 1 72	8	1.817	3.62	0.51	0.438	0.000148	0.318	0.1	0.87	0.00218	NA	506850.0	0.6	0.638	8.82e-05	0.447	0.1	0.8	0.00802	NA
HCC1806	Sirolimus	1	72	sigmoid	sigmoid	HCC1806 rapamycin 0 1 72	8	2.796	1.35	0.775	0.187	0.00019	0.706	0.1	0.661	0.039	NA	1.05	0.717	0.76	1e-05	0.657	0.1	0.68	0.0328	NA
Hs 578T	Sirolimus	1		sigmoid	sigmoid	Hs578T rapamycin 1	8	2.013	110643.0	0.587	0.358	0.000237	0.432	0.1	0.879	0.00178	NA	9.61e+11	0.628	0.672	0.000175	0.487	0.1	0.851	0.00332	NA
HCC1806	Sirolimus	3	72	sigmoid	sigmoid	HCC1806 rapamycin 0 3 72	8	3.249	0.223	0.805	0.162	0.000183	0.746	0.1	0.663	0.0382	NA	1.05	0.717	0.76	1e-05	0.657	0.1	0.68	0.0328	NA
HCC1806	Sirolimus	2	72	sigmoid	sigmoid	HCC1806 rapamycin 0 2 72	8	2.881	0.901	0.782	0.182	0.000189	0.714	0.1	0.661	0.0388	NA	149.0	0.717	0.76	0.000153	0.626	0.1	0.634	0.0489	NA
HCC70	Sirolimus	1	72	sigmoid	sigmoid	HCC70 rapamycin 0 1 72	8	1.416	37.6	0.533	0.397	0.00426	0.298	0.1	0.742	0.0172	NA	125000000.0	0.687	0.732	0.00186	0.541	0.1	0.74	0.0175	NA
BT-20	AS605240	2	72	sigmoid	sigmoid	BT20 AS-605240 0 2 72	8	1.846	4509270.0	0.729	0.203	320.0	0.31	0.101	0.845	0.00373	NA	4.4e+12	0.764	0.821	56.5	0.46	0.101	0.843	0.00388	NA
BT-549	TGX221	3	72	sigmoid	sigmoid	BT549 TGX-221 0 3 72	8	1.768	93790.0	0.805	0.0889	320.0	0.356	0.22	0.707	0.0251	NA	49050766.0	0.834	0.923	320.0	0.461	0.214	0.703	0.0263	NA
HCC38	CAL-101	3	72	sigmoid	sigmoid	HCC38 idelalisib 0 3 72	8	1.443	Inf	0.851	0.0804	4.08	0.726	0.225	0.706	0.0254	NA	Inf	0.894	0.943	4.27	0.804	0.222	0.707	0.0252	NA
BT-20	AS605240	1	72	sigmoid	sigmoid	BT20 AS-605240 0 1 72	8	2.142	Inf	0.817	0.0993	3.91	0.634	0.244	0.861	0.00271	NA	Inf	0.814	0.897	3.87	0.629	0.237	0.854	0.00311	NA
HCC38	TGX221	3	72	sigmoid	sigmoid	HCC38 TGX-221 0 3 72	8	1.484	3688.0	0.815	0.0743	320.0	0.243	0.273	0.867	0.00233	NA	3261706.0	0.866	0.945	320.0	0.458	0.269	0.867	0.00238	NA
BT-20	AS605240	3	72	sigmoid	sigmoid	BT20 AS-605240 0 3 72	8	2.607	Inf	0.845	0.0823	4.13	0.662	0.292	0.729	0.0199	NA	Inf	0.81	0.897	3.97	0.589	0.284	0.712	0.0239	NA
BT-549	AS605240	3	72	sigmoid	sigmoid	BT549 AS-605240 0 3 72	8	1.796	Inf	0.863	0.066	4.3	0.721	0.307	0.896	0.00112	NA	Inf	0.881	0.942	4.35	0.756	0.302	0.894	0.00118	NA
HCC70	Dactolisib	1	72	sigmoid	sigmoid	HCC70 dactolisib 0 1 72	8	1.400	0.0808	-0.0667	0.501	3.34	-1.0	0.295	0.963	5.02e-05	NA	0.753	0.344	0.673	0.753	0.0	0.308	0.962	5.37e-05	NA
BT-20	KIN001-244	2	72	sigmoid	sigmoid	BT20 KIN001-244 0 2 72	8	1.742	Inf	0.85	0.0644	4.47	0.713	0.316	0.721	0.0218	NA	Inf	0.873	0.945	4.51	0.757	0.309	0.715	0.0231	NA

|<
<<
Previous
Page 4 of 18
Next
>>
>
76 to 100 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)